» Articles » PMID: 6811355

Pharmacokinetics of Intravenous Glibenclamide Investigated by a High Performance Liquid Chromatographic Assay

Overview
Journal Diabetologia
Specialty Endocrinology
Date 1982 Jul 1
PMID 6811355
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

A simple high performance liquid chromatographic assay for the determination of plasma glibenclamide concentrations is described. This resolved glibenclamide from normal plasma constituents. The calibration curve of the assay was linear over the range 10-500 microgram/l and the minimum level of detection was 2 microgram/l. Within-assay coefficients of variation were 11.6% (20 microgram/l); 5.3% (50 microgram/l); 6.8% (100 microgram/l); between-assay coefficients of variation were 8.4% (20 microgram/l); 4.7% (50 microgram/l) and 7.4% (100 microgram/l). The assay was used to study the pharmacokinetics of a 1 mg intravenous dose of glibenclamide in eight normal subjects. The mean half-life was found to be 1.47 +/- 0.42 h (SD) and no evidence for a non-linear beta-phase or slowly equilibrating 'deep' compartment was found although this could not be rigorously excluded. The mean systemic drug clearance was 78 +/- 29 ml X h-1 X kg-1 and the apparent volume of distribution in the beta-phase was 155 +/- 44 ml/kg. The median time of maximum response of plasma immunoreactive insulin was 25 min and the median time of maximum blood glucose response was 53 min. No correlation could be found between the pharmacokinetics of glibenclamide and these responses in fasted normal individuals.

Citing Articles

A radioimmunoassay for determination of glibenclamide and other sulfonylureas.

Heptner W, Badian M, Baudner S, Hellstern C, Irmisch R, Rupp W Pharm Res. 2013; 1(5):215-20.

PMID: 24277331 DOI: 10.1023/A:1016321313510.


Comparison of antihyperglycemic effects of creatine and glibenclamide in type II diabetic patients.

Rocic B, Znaor A, Rocic P, Weber D, Vucic Lovrencic M Wien Med Wochenschr. 2011; 161(21-22):519-23.

PMID: 21792527 DOI: 10.1007/s10354-011-0905-7.


Hypoglycemia associated with the use of fluoxetine.

Deeg M, Lipkin E West J Med. 1996; 164(3):262-3.

PMID: 8775944 PMC: 1303427.


The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics.

Jaber L, Antal E, Slaughter R, Welshman I Eur J Clin Pharmacol. 1993; 45(5):459-63.

PMID: 8112376 DOI: 10.1007/BF00315518.


The effect of hyperglycaemia on the absorption of glibenclamide in patients with non-insulin-dependent diabetes mellitus.

Hoffman A, Fischer Y, Gilhar D, Raz I Eur J Clin Pharmacol. 1994; 47(1):53-5.

PMID: 7988624 DOI: 10.1007/BF00193478.


References
1.
Rupp W, Christ O, Heptner W . [Resorption, excretion and metabolism after intravenous and oral administration of HB 419-14C in man]. Arzneimittelforschung. 1969; 19(8):Suppl:1428-34. View

2.
Balant L, ZAHND G, Weber F, Fabre J . Behaviour of glibenclamide on repeated administration to diabetic patients. Eur J Clin Pharmacol. 1977; 11(1):19-25. DOI: 10.1007/BF00561783. View

3.
Trinder P . Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol. 1969; 22(2):158-61. PMC: 474026. DOI: 10.1136/jcp.22.2.158. View

4.
Fell P, Stevens M . Pharmacokinetics--uses and abuses. Eur J Clin Pharmacol. 1975; 8(3-4):241-8. DOI: 10.1007/BF00567122. View

5.
Balant L, Fabre J, ZAHND G . Comparison of the pharmacokinetics of glipizide and glibenclamide in man. Eur J Clin Pharmacol. 1975; 8(1):63-9. DOI: 10.1007/BF00616416. View